Solid Biosciences Added to the Nasdaq Biotechnology Index
23. Dezember 2024 16:05 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for...
Solid Biosciences Announces Collaboration with Mayo Clinic to Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies
04. Dezember 2024 08:00 ET
|
Solid Biosciences Inc.
- Solid Biosciences to collaborate with Mayo Clinic’s genetic cardiology disease laboratory - - Solid to receive exclusive worldwide licenses to AAV-based Suppression-Replacement gene therapy...
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03. Dezember 2024 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and...
Solid Biosciences to Participate at Upcoming Investor Conferences
26. November 2024 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for...
Solid Biosciences to Present at the Jefferies London Healthcare Conference
14. November 2024 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for...
Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates
06. November 2024 16:05 ET
|
Solid Biosciences Inc.
- Duchenne: Dosing completed for first three patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1...
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04. November 2024 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and...
Solid Biosciences to Participate at the Truist Securities BioPharma Symposium
31. Oktober 2024 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for...
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02. Oktober 2024 16:15 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and...
Solid Biosciences to Participate at Chardan’s 8th Annual Genetic Medicines Conference
23. September 2024 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for...